NL-OMON33296已完成2 期
Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study - Treatment of acute inner ear tinnitus
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Persistent tinnitus following acute acoustic trauma or sudden deafness or acute otitis media with onset less than three months ago (i.e. acute tinnitus)
- •Tinnitus provoking incident of acute acoustic trauma or sudden deafness or acute otitis media is documented by medical report
- •Minimum Masking Level (MML) of at least 5 dB SL
- •Age >= 18 years and <= 65 years
- •Negative pregnancy test for women of childbearing potential
- •Willing and able to attend the on-study visits
- •Written informed consent before participation in the study
排除标准
- •Tinnitus that is not completely maskable
- •Fluctuating tinnitus
- •Intermittent tinnitus
- •Meniere*s Disease
- •Acute or chronic otitis media or otitis externa
- •Any ongoing therapy known as potentially tinnitus-inducing (e.g. aminoglycosides, cisplatin, loop diuretics, high doses of aspirin, quinine etc.)
- •Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks, e.g. prednisolone, dexamethasone, pentoxyfilline, betahistine, diazepam, carbamazepine, sodium valproate and antidepressants
- •Concomitant use of any other NMDA receptor antagonist (e.g. memantine, dextromethorphan, ifenprodil)
- •Any drug-based therapy for acute otitis media that is ongoing or was performed in the past 2 weeks
- •Any ongoing or planned concomitant medication for the treatment of tinnitus until 90 days after study drug application
- •History or presence of drug abuse or alcoholism
- •Any clinically relevant respiratory, cardiovascular, neurological (except vertigo), or psychiatric disorder
- •Known hypersensitivity, allergy or intolerance to the study medication or any history of severe abnormal drug reaction
- •Women who are breast-feeding, pregnant or who plan a pregnancy during the trial
- •Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner
- •Concurrent participation in another clinical trial with an investigational drug or participation in another clinical trial with an investigational drug within 30 days prior to study entry
研究者
相似试验
进行中（未招募）
不适用
Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II StudyAcute inner ear tinnitus following acute acoustic trauma, sudden deafness, or acute otitis media.MedDRA version: 13.1Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2008-005178-10-DEAuris Medical AG240
进行中（未招募）
不适用
Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II StudyEUCTR2008-005178-10-NLAuris Medical AG240
进行中（未招募）
1 期
Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II StudyEUCTR2008-005178-10-BEAuris Medical AG240
已完成
2 期
Efficacy of AM 101 in Patients With Acute Inner Ear TinnitusTinnitusNCT00860808Auris Medical AG248
进行中（未招募）
不适用
Safety of AM-101 in Patients with Acute Inner Ear Tinnitus from Noise Trauma: a Dose-Finding Phase I/II StudyEUCTR2006-002692-41-DEaboratoires Auris SAS